Volatile day for CAR-T biotechs after FDA announces cancer safety review
As if biotechs needed any more bad news, CAR-T therapy companies saw shares tumble on the news that the FDA will investigate the “serious risk” of subsequent, secondary cancers that can occur after treatment with the therapies. Autolus Therapeutics, developer of autologous T-cell therapies,…
#fda #autolustherapeutics #nkarta #legendbiotech #carvyktiwith #johnsonjohnson #bristolmyerssquibb #gilead #williamblair #poseida